Jefferies Starts NuCana (NCNA) at Buy

Jefferies initiates coverage on NuCana (NASDAQ: NCNA) with a Buy rating and a price target of $25.00.

Analyst Eun Yang believes the broadly available ProTide platform is a positive and views success in one indication or product could translate into success in additional indications or products. The analyst sees multiple clinical data for lead product Acelarin in 2018. Yang believes product sales could grow to EUR 500 million in 2022 from potential approval of 5 various cancer types for Acelarin & NUC-3373.

For an analyst ratings summary and ratings history on NuCana click here. For more ratings news on NuCana click here.

Shares of NuCana closed at $14.08 Friday.

You May Also Be Interested In

• Evercore ISI Starts NVIDIA (NVDA) at Outperform
• Citi Downgrades Endeavor Group Holdings Inc (EDR) to Neutral
• Perfect World Co Ltd (002624:CH) PT Lowered to RMB11.90 at Jefferies